CN101815715B - 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用 - Google Patents

7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用 Download PDF

Info

Publication number
CN101815715B
CN101815715B CN200880020155.4A CN200880020155A CN101815715B CN 101815715 B CN101815715 B CN 101815715B CN 200880020155 A CN200880020155 A CN 200880020155A CN 101815715 B CN101815715 B CN 101815715B
Authority
CN
China
Prior art keywords
compound
cancer
compound according
preparation
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880020155.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101815715A (zh
Inventor
F·博诺
O·杜克洛斯
G·麦克科特
A·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101815715A publication Critical patent/CN101815715A/zh
Application granted granted Critical
Publication of CN101815715B publication Critical patent/CN101815715B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
CN200880020155.4A 2007-06-13 2008-06-11 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用 Active CN101815715B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0704193 2007-06-13
FR0704193A FR2917413B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
PCT/FR2008/000794 WO2009007536A2 (fr) 2007-06-13 2008-06-11 Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique

Publications (2)

Publication Number Publication Date
CN101815715A CN101815715A (zh) 2010-08-25
CN101815715B true CN101815715B (zh) 2014-10-08

Family

ID=38961501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880020155.4A Active CN101815715B (zh) 2007-06-13 2008-06-11 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用

Country Status (28)

Country Link
US (2) US8263614B2 (https=)
EP (1) EP2158194B1 (https=)
JP (1) JP5346337B2 (https=)
KR (1) KR20100019507A (https=)
CN (1) CN101815715B (https=)
AR (1) AR066955A1 (https=)
AT (1) ATE509923T1 (https=)
AU (1) AU2008274100B2 (https=)
BR (1) BRPI0813809B1 (https=)
CA (1) CA2690349C (https=)
CO (1) CO6150157A2 (https=)
CY (1) CY1111748T1 (https=)
DK (1) DK2158194T3 (https=)
EA (1) EA016552B1 (https=)
ES (1) ES2366629T3 (https=)
FR (1) FR2917413B1 (https=)
HR (1) HRP20110550T1 (https=)
IL (1) IL202677A (https=)
IN (1) IN2009KN04279A (https=)
MA (1) MA31674B1 (https=)
ME (1) ME00957B (https=)
MX (1) MX2009013514A (https=)
MY (1) MY146939A (https=)
NZ (1) NZ581883A (https=)
PL (1) PL2158194T3 (https=)
PT (1) PT2158194E (https=)
SI (1) SI2158194T1 (https=)
WO (1) WO2009007536A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease
WO2013072882A1 (en) * 2011-11-18 2013-05-23 Actelion Pharmaceuticals Ltd 2 -amino- 1, 8 -naphthyridine-3 -carboxamide derivatives as antimicrobial agents
CN116509854B (zh) * 2023-04-26 2025-05-23 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种萘啶酮衍生物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239094A (zh) * 1998-06-12 1999-12-22 拜尔公司 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69631423T2 (de) 1995-08-02 2004-12-02 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
HUP0002353A3 (en) 1998-01-29 2001-11-28 Daiichi Asubio Pharma Co Ltd 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
MXPA03010099A (es) 2001-05-08 2004-03-10 Schering Ag Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.
JP4460221B2 (ja) 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
US7148357B2 (en) 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US20070254877A1 (en) * 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239094A (zh) * 1998-06-12 1999-12-22 拜尔公司 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘明亮.喹诺酮的演变.《国外医药（抗生素分册）》.2006,第27卷(第2期),69-75. *

Also Published As

Publication number Publication date
ES2366629T3 (es) 2011-10-24
IL202677A (en) 2014-12-31
JP2010529179A (ja) 2010-08-26
EA201070010A1 (ru) 2010-06-30
WO2009007536A8 (fr) 2010-01-07
SI2158194T1 (sl) 2011-10-28
CA2690349A1 (fr) 2009-01-15
PL2158194T3 (pl) 2011-10-31
CO6150157A2 (es) 2010-04-20
MA31674B1 (fr) 2010-09-01
ME00957B (me) 2012-06-20
CA2690349C (fr) 2015-11-24
JP5346337B2 (ja) 2013-11-20
US20120238598A1 (en) 2012-09-20
MX2009013514A (es) 2010-01-27
NZ581883A (en) 2011-05-27
AU2008274100B2 (en) 2013-07-11
EP2158194B1 (fr) 2011-05-18
US20100144782A1 (en) 2010-06-10
WO2009007536A2 (fr) 2009-01-15
IN2009KN04279A (https=) 2015-08-28
HK1143590A1 (en) 2011-01-07
BRPI0813809A2 (pt) 2020-02-04
EP2158194A2 (fr) 2010-03-03
DK2158194T3 (da) 2011-09-12
IL202677A0 (en) 2010-06-30
EA016552B1 (ru) 2012-05-30
FR2917413B1 (fr) 2009-08-21
FR2917413A1 (fr) 2008-12-19
AR066955A1 (es) 2009-09-23
MY146939A (en) 2012-10-15
CY1111748T1 (el) 2015-10-07
CN101815715A (zh) 2010-08-25
KR20100019507A (ko) 2010-02-18
US8263614B2 (en) 2012-09-11
PT2158194E (pt) 2011-08-17
WO2009007536A3 (fr) 2009-03-19
ATE509923T1 (de) 2011-06-15
BRPI0813809B1 (pt) 2021-05-25
AU2008274100A1 (en) 2009-01-15
US8586602B2 (en) 2013-11-19
HRP20110550T1 (hr) 2011-09-30

Similar Documents

Publication Publication Date Title
CN101815715B (zh) 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用
CN101679427B (zh) 7-炔基-1,8-萘啶酮的衍生物、其制备和其在治疗学中的应用
US8841304B2 (en) Pyrrolopyridines as kinase inhibitors
JP2009528989A (ja) Ｔｌｒ７変調剤としての３−デアザプリン誘導体
CN102099336B (zh) 苯基氨基异烟酰胺化合物
SK9122003A3 (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
JP2000516932A (ja) 新規のベンゾフラン―４―カルボキサミド
CN101384593A (zh) 用作tlr7调节剂的3-脱氮嘌呤衍生物
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
HK1143590B (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
HK1141790B (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
HK1127920A (en) 3-deazapurine derivatives as tlr7 modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1143590

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1143590

Country of ref document: HK

CP03 Change of name, title or address

Address after: 46 Grand EST Avenue Paris France

Patentee after: Sai Nuofei

Country or region after: France

Address before: Paris France

Patentee before: SANOFI-AVENTIS

Country or region before: France

CP03 Change of name, title or address